CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today announced that it had enrolled the first patient in a planned Phase 3, single-arm, open label observational safety study for its injectable NSAID, Dyloject™ (diclofenac sodium). The study is intended to supplement the Company’s summary of integrated patient safety data base, a part of its New Drug Application (NDA) for Dyloject in the United States, planned for submission to the FDA in 2009.
